T2w images with overlays of lesion boundaries, DWI-derived ADC, DCE-derived 𝐾𝑡𝑟𝑎𝑛𝑠, and CDI𝑠 for six patient cases. (a, b) Two patients with csPCa in the PZ. (c, d) Two patients with csPCa in the TZ. (e) A patient with csPCa in the PZ and insPCa in the TZ. (f) A patient with csPCa in the AS and insPCa in the PZ.

March 28, 2022 — A new form of magnetic resonance imaging (MRI) that makes cancerous tissue glow in medical images could help doctors more accurately detect and track the progression of cancer over time.

The innovation, developed by researchers at the University of Waterloo, creates images in which cancerous tissue appears to light up compared to healthy tissue, making it easier to see.

"Our studies show this new technology has promising potential to improve cancer screening, prognosis and treatment planning," said Alexander Wong, Canada Research Chair in Artificial Intelligence and Medical Imaging and a professor of systems design engineering at Waterloo.

Irregular packing of cells leads to differences in the way water molecules move in cancerous tissue compared to healthy tissue. The new technology, called synthetic correlated diffusion imaging, highlights these differences by capturing, synthesizing and mixing MRI signals at different gradient pulse strengths and timings.

In the largest study of its kind, the researchers collaborated with medical experts at the Lunenfeld-Tanenbaum Research Institute, several Toronto hospitals and the Ontario Institute for Cancer Research to apply the technology to a cohort of 200 patients with prostate cancer.

Compared to standard MRI techniques, synthetic correlated diffusion imaging was better at delineating significant cancerous tissue, making it a potentially powerful tool for doctors and radiologists.

"Prostate cancer is the second most common cancer in men worldwide and the most frequently diagnosed cancer among men in more developed countries," said Wong, also a director of the Vision and Image Processing (VIP) Lab at Waterloo. "That's why we targeted it first in our research.

"We also have very promising results for breast cancer screening, detection, and treatment planning. This could be a game-changer for many kinds of cancer imaging and clinical decision support."

The core research team also included Hayden Gunraj and Vignesh Sivan, engineering graduate students at Waterloo, and Dr. Masoom Haider of the Lunenfeld-Tanenbaum Research Institute. 

Their paper, Synthetic correlated diffusion imaging hyperintensity delineates clinically significant prostate cancer, appears in the journal Scientific Reports.

For more information: www.uwaterloo.ca


Related Content

News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Radiation Therapy

July 22, 2024 — RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from ...

Time July 22, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
Subscribe Now